First Trust Advisors
ESPR

First Trust Advisors’s Esperion Therapeutics ESPR Stock Holding History

First Trust Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-22,771
Closed -$114K – 2536
2021
Q4 		$114K Buy
22,771
+346
+2% +$2.77K ﹤0.01% 2496
2021
Q3 		$270K Buy
22,425
+12,184
+119% +$177K ﹤0.01% 2403
2021
Q2 		$217K Buy
10,241
+784
+8% +$18.9K ﹤0.01% 2415
2021
Q1 		$265K Sell
9,457
-26,634
-74% -$786K ﹤0.01% 2340
2020
Q4 		$938K Buy
36,091
+21,067
+140% +$631K ﹤0.01% 1918
2020
Q3 		$558K Buy
15,024
+10,699
+247% +$424K ﹤0.01% 2005
2020
Q2 		$222K Buy
+4,325
New +$181K ﹤0.01% 2221
2017
Q4 		– Sell
-9,205
Closed -$461K – 2410
2017
Q3 		$461K Sell
9,205
-468
-5% -$22.6K ﹤0.01% 2114
2017
Q2 		$448K Sell
9,673
-10,529
-52% -$387K ﹤0.01% 2110
2017
Q1 		$713K Buy
+20,202
New +$463K ﹤0.01% 1956

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

First Trust Advisors's ESPR Position: Q1 2022 in Review

First Trust Advisors sold out of Esperion Therapeutics (ESPR) in Q1 2022, closing a stake of 22,771 shares — an estimated $114K sold.

First Trust Advisors first reported a position in ESPR in Q1 2017 and held it in 10 quarters. The position peaked at $938K in Q4 2020. 132 funds tracked by Wall St. Rank hold ESPR as of Q1 2022.

  • First Trust Advisors reported no remaining Esperion Therapeutics position as of Q1 2022 after selling out during the quarter.
  • First Trust Advisors sold 22,771 Esperion Therapeutics shares in Q1 2022, an estimated $114K.
  • First Trust Advisors first reported a position in Esperion Therapeutics in Q1 2017 and held it in 10 quarters.
  • First Trust Advisors's Esperion Therapeutics position peaked at $938K in Q4 2020.
  • 132 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2022.

Based on First Trust Advisors's 13F filing for Q1 2022, filed 13 May 2022.